Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 12:345:e4535.
doi: 10.1136/bmj.e4535.

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study

J P Sheppard  1 , S Singh, K Fletcher, R J McManus, J Mant
Affiliations

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study

J P Sheppard et al. BMJ. .

Abstract

Objectives: To establish the impact of age and sex on primary preventive treatment for cardiovascular disease in a typical primary care population.

Design: Cross sectional study of anonymised patient records.

Participants: All 41,250 records of patients aged ≥ 40 registered at 19 general practices in the West Midlands, United Kingdom, were extracted and analysed.

Main outcome measures: Patients' demographics, risk factors for cardiovascular disease (blood pressure, total cholesterol concentration), and prescriptions for primary preventive drugs were extracted from patients' records. Patients were subdivided into five year age bands up to 85 (patients aged ≥ 85 were analysed as one group) and prescribing trends across the population were assessed by estimating the proportion of patients prescribed with antihypertensive drug or statin drug, or both, in each group.

Results: Of the 41,250 records screened in this study, 36,679 (89%) patients did not have a history of cardiovascular disease and therefore could be considered for primary preventive treatment. The proportion receiving antihypertensive drugs increased with age (from 5% (378/6978) aged 40-44 to 57% (621/1092) aged ≥ 85) as did the proportion taking statins up to the age of 74 (from 3% (201/6978) aged 40-44 to 29% (675/2367) aged 70-74). In those aged 75 and above, the odds of a receiving prescription for a statin (relative to the 40-44 age group) decreased with every five year increment in age (odds ratio 12.9 (95% confidence interval 10.8 to 15.3) at age 75-79 to 5.7 (4.6 to 7.2) at age ≥ 85; P<0.001). There were no consistent differences in prescribing trends by sex.

Conclusions: Previously described undertreatment of women in secondary prevention of cardiovascular disease was not observed for primary prevention. Low use of statins in older people highlights the need for a stronger evidence base and clearer guidelines for people aged over 75.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Proportion of patients prescribed antihypertensive drugs and mean blood pressure of treated and untreated patients
None
Fig 2 Proportion of patients prescribed cholesterol lowering drugs and mean cholesterol concentration of treated and untreated patients
None
Fig 3 Proportion of patients prescribed primary preventive drug treatment in each age group by sex
See this image and copyright information in PMC

References

    1. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. WHO Press, 2007.
    1. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. CG127, 2011.
    1. National Institute for Health and Clinical Excellence. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. CG067, 2008. www.nice.org.uk/CG067. - PubMed
    1. British Medical Association, NHS Employers. Quality and outcomes framework guidance for GMS contract 2009/10: delivering investment in general practice. EGUI05501, 2009.
    1. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. - PubMed

Publication types

MeSH terms

Substances